Prosomnus IncOTC Pink - Current Information:OSAPQ
- LAST PRICE0.0250
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.0250/ 100
- Ask / Lots0.0300/ 100
- Open / Previous Close0.0250 / 0.0250
- Day Range
- 52 Week Range
- Volume160
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | OSAPQ |
|---|---|---|
| 09:32 ET | 160 | 0.025 |
May 30, 2024
May 16, 2024
Press Release: ProSomnus Announces Strong First Quarter 2024 Revenue Growth, from 8:46AM ET on Thursday May 16, 2024 by Dow Jones
8:46AM ET on Thursday May 16, 2024 by Dow JonesProSomnus Announces Strong First Quarter 2024 Revenue Growth, from 8:42AM ET on Thursday May 16, 2024 by Dow Jones
8:42AM ET on Thursday May 16, 2024 by Dow Jones
May 13, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Prosomnus Inc | 521.8K | 0.0x | --- |
Allied Healthcare Products Inc | 400.0 | 0.0x | --- |
Telesis Bio Inc | 6.4M | -0.1x | --- |
Aamaxan Transport Group Inc | 1.6K | 0.0x | --- |
Micron Solutions Inc | 1.7M | -0.7x | --- |
Ekso Bionics Holdings Inc | 20.0M | -1.1x | --- |
Company Information
ProSomnus, Inc. is a medical technology company. The Company is focused on the development, manufacturing and marketing of precision intraoral medical devices, a novel non-invasive option for treating and managing patients with obstructive sleep apnea (OSA). Its intraoral medical devices are engineered to precisely track the treatment plan and anatomy for each patient. The Company's devices have demonstrated efficacy, safety, adherence, and overall outcomes in a growing body of clinical investigations. Its precision intraoral devices are FDA-cleared, patented, and covered by commercial medical insurance, Medicare, TRICARE and many Government-sponsored healthcare plans around the world, representing over 200 million covered lives. The Company’s products include ProSomnus EVO Sleep and Snore Device, ProSomnus EVO SELECT Sleep and Snore Device, ProSomnus EVO [PH] Sleep and Snore Device, ProSomnus [CA] LP Sleep and Snore Device and ProSomnus [MOG] Morning Occlusal Guide.
Contact Information
- Headquarters
- 5675 Gibraltar DrPLEASANTON, CA, United States 94588
- Phone
- ---
- Fax
- 302-636-5454
Executives
- Executive Chairman of the Board
- Laing Rikkers
- Chief Executive Officer, Director
- Leonard Liptak
- Chief Financial Officer, Principal Accounting Officer
- Brian Dow
- Chief Technical Officer
- Sung Kim
- Lead Independent Director
- William Johnson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $521.8K |
|---|---|
Revenue (TTM) | $29.3M |
Shares Outstanding | 17.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.15 |
Book Value | $-1.53 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -92.84% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
